A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of an "Inclisiran First" Implementation Strategy to Usual Care on LDL Cholesterol (LDL-C) in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C (≥70 mg/dL) Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms V-INITIATE; VICTORION-INITIATE
- Sponsors Novartis Pharmaceuticals
- 06 Apr 2024 Results from this trial presented in a Novartis media release.
- 06 Apr 2024 According to a Novartis media release, Michael Koren is the primary investigator of this trial.
- 19 Dec 2023 Status changed from active, no longer recruiting to completed.